Spago Nanomedical AB (publ) develops nanomaterials for cancer diagnostics and treatment.
+ 1 more risk
Price History & Performance
|Historical stock prices|
|Current Share Price||kr6.34|
|52 Week High||kr4.70|
|52 Week Low||kr9.44|
|1 Month Change||-7.85%|
|3 Month Change||-3.65%|
|1 Year Change||1.60%|
|3 Year Change||-51.79%|
|5 Year Change||-51.23%|
|Change since IPO||-54.71%|
Recent News & Updates
We're Not Worried About Spago Nanomedical's (STO:SPAGO) Cash Burn
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
We're Interested To See How Spago Nanomedical (STO:SPAGO) Uses Its Cash Hoard To Grow
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Loss-Making Spago Nanomedical AB (publ) (STO:SPAG) Set To Breakeven
Spago Nanomedical AB (publ) ( STO:SPAG ) is possibly approaching a major achievement in its business, so we would like...
|SPAGO||SE Biotechs||SE Market|
Return vs Industry: SPAGO underperformed the Swedish Biotechs industry which returned 16.7% over the past year.
Return vs Market: SPAGO underperformed the Swedish Market which returned 29.5% over the past year.
Stable Share Price: SPAGO is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: SPAGO's weekly volatility (6%) has been stable over the past year.
About the Company
Spago Nanomedical AB (publ) develops nanomaterials for cancer diagnostics and treatment. It offers SpagoPix, a cancer selective MRI contrast agent; and Tumorad, a tumor selective radiation treatment. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014.
Spago Nanomedical Fundamentals Summary
|SPAGO fundamental statistics|
Is SPAGO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SPAGO income statement (TTM)|
|Cost of Revenue||kr11.28m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.65|
|Net Profit Margin||-377.35%|
How did SPAGO perform over the long term?See historical performance and comparison
Is Spago Nanomedical undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate SPAGO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate SPAGO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: SPAGO is unprofitable, so we can't compare its PE Ratio to the Swedish Biotechs industry average.
PE vs Market: SPAGO is unprofitable, so we can't compare its PE Ratio to the Swedish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SPAGO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SPAGO is good value based on its PB Ratio (1.3x) compared to the SE Biotechs industry average (4x).
How is Spago Nanomedical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SPAGO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SPAGO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SPAGO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SPAGO's revenue (25.7% per year) is forecast to grow faster than the Swedish market (4.2% per year).
High Growth Revenue: SPAGO's revenue (25.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SPAGO's Return on Equity is forecast to be high in 3 years time
How has Spago Nanomedical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SPAGO is currently unprofitable.
Growing Profit Margin: SPAGO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SPAGO is unprofitable, and losses have increased over the past 5 years at a rate of 26.9% per year.
Accelerating Growth: Unable to compare SPAGO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SPAGO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (9.7%).
Return on Equity
High ROE: SPAGO has a negative Return on Equity (-12.99%), as it is currently unprofitable.
How is Spago Nanomedical's financial position?
Financial Position Analysis
Short Term Liabilities: SPAGO's short term assets (SEK78.4M) exceed its short term liabilities (SEK7.1M).
Long Term Liabilities: SPAGO's short term assets (SEK78.4M) do not cover its long term liabilities (SEK-1,000.0).
Debt to Equity History and Analysis
Debt Level: SPAGO is debt free.
Reducing Debt: SPAGO has no debt compared to 5 years ago when its debt to equity ratio was 7.9%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SPAGO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if SPAGO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Spago Nanomedical current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SPAGO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SPAGO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SPAGO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SPAGO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SPAGO's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mats Hansen (50 yo)
Dr. Mats Hansen, MSc., PhD, serves as the Chief Executive Officer of Spago Nanomedical AB (publ). Dr. Hansen has 20 years of experience from different companies in the life science industry. He served at A...
CEO Compensation Analysis
Compensation vs Market: Mats's total compensation ($USD187.91K) is below average for companies of similar size in the Swedish market ($USD268.92K).
Compensation vs Earnings: Mats's compensation has been consistent with company performance over the past year.
Experienced Management: SPAGO's management team is considered experienced (2.8 years average tenure).
Experienced Board: SPAGO's board of directors are considered experienced (3.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 30.6%.
Spago Nanomedical AB (publ)'s employee growth, exchange listings and data sources
- Name: Spago Nanomedical AB (publ)
- Ticker: SPAGO
- Exchange: OM
- Founded: 2007
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: kr261.096m
- Shares outstanding: 41.18m
- Website: https://spagonanomedical.se
Number of Employees
- Spago Nanomedical AB (publ)
- Scheelevägen 22
- Skåne County
- 223 63
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/16 18:02|
|End of Day Share Price||2021/10/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.